Future studies are needed to identify which people with MS are most likely to benefit from taking a GLP-1, the safest dosing strategies, and whether these medications have long-term disease-modifying effects in MS, she says
Seventy-five percent of the cohort was white (n=76), 2% identified as other (n=2), 23% identified as black (n=24), and 1% (n=1) was Hispanic
Active membership required
[1] [2] The extent of human milk transfer, bioavailability to the infant, and potential systemic effects remain unknown
As research continues, GLP-1s therapeutic potential in AD remains a promising frontier (Gejl et al., 2016
Without knowing the exact amount in the proprietary blend, you are taking it on faith that Tranont included a therapeutically relevant dose